Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yangfan New Materials (Zhejiang) Co., Ltd. (300637.SZ)
Hangzhou, CN
Yangfan New Materials (Zhejiang) Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of ultraviolet (UV) curing products, sulfur-containing fine chemicals, and related new materials in China and internationally. The company offers 4-fluoro thiophenol, diphenyl sulfide, diphenyl disulfide, cyclopropanesulfonyl amide, and thioacetamide; and intermediates, including thiophenol, phenyl sulfide, thioanisole, thiofuran, pyridine and aniline, sulfone and sulfoxide, and other products. It also provides photoinitiators; and light-curable materials, such as HRI monomers and dispersions, high refractive index UV adhesives, optically bonding and electronic assembly UV adhesives, industrial bonding UV adhesives, and photosensitive resins for special applications. The company’s products are used in medicine, pesticides, dyes, and other fields. It also exports its products. In addition, the company provides technical services. The company was formerly known as Zhejiang Yangfan New Materials Co., Ltd. and changed its name to Yangfan New Materials (Zhejiang) Co., Ltd. in May 2025. Yangfan New Materials (Zhejiang) Co., Ltd. was founded in 2002 and is based in Hangzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.35% | -15.09% | -11.40% | -27.70% | -18.55% | -15.82% | -5.50% | +34.11% | +2.20% | +34.49% | +34.49% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+25.8% ★ Q1'26: -12.5% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+132.4% ★ Q1'26: -131.5% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%-4.9% Q1'26: -4.8% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+3.3% Q1'26: -1.8% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+2.7% Q1'26: -1.3% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×3.99× Q1'26: -32.62× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
525.98M
est: 597.18M (-11.9%)
|
511.69M
est: 632.00M (-19.0%)
|
494.41M
est: 1.10B (-54.9%)
|
1.32B
est.
|
731.40M
est: 597.18M (+22.5%)
|
919.81M
est: 632.00M (+45.5%)
|
1.10B
1.10B – 1.10B
+73.4% YoY
|
1.32B
1.32B – 1.32B
+20.0% YoY
|
| EBITDA |
184.90M
est: 58.07M (+218.4%)
|
145.63M
est: 61.46M (+137.0%)
|
77.17M
est: 106.58M (-27.6%)
|
127.88M
est.
|
51.37M
est: 52.37M (-1.9%)
|
108.25M
est: 55.42M (+95.3%)
|
96.12M
96.12M – 96.12M
+73.4% YoY
|
115.32M
115.32M – 115.32M
+20.0% YoY
|
| EBIT |
160.83M
est: -2.14M (+7,630.5%)
|
117.19M
est: -2.26M (+5,284.5%)
|
39.91M
est: -3.92M (+1,118.2%)
|
-4.70M
est.
|
-26.42M
est: -7.74M (-241.4%)
|
30.14M
est: -8.19M (+468.0%)
|
-14.20M
-14.20M – -14.20M
-73.4% YoY
|
-17.04M
-17.04M – -17.04M
-20.0% YoY
|
| Net Income |
137.48M
est: 140.85M (-2.4%)
|
101.06M
est: 140.85M (-28.2%)
|
27.65M
est: 234.75M (-88.2%)
|
281.70M
est.
|
-46.04M
est: 140.89M (-132.7%)
|
15.19M
est: 140.89M (-89.2%)
|
234.82M
234.82M – 234.82M
+66.7% YoY
|
281.78M
281.78M – 281.78M
+20.0% YoY
|
| SGA |
57.82M
est: 19.76M (+192.6%)
|
64.87M
est: 20.92M (+210.1%)
|
55.68M
est: 36.27M (+53.5%)
|
43.52M
est.
|
68.85M
est: 49.56M (+38.9%)
|
21.75M
est: 52.45M (-58.5%)
|
90.96M
90.96M – 90.96M
+73.4% YoY
|
109.14M
109.14M – 109.14M
+20.0% YoY
|
| EPS |
0.60
est: 0.60 (+0.0%)
|
0.44
est: 0.60 (-26.7%)
|
0.12
est: 1.00 (-88.0%)
|
1.20
est.
|
-0.20
est: 0.60 (-133.3%)
|
0.06
est: 0.60 (-89.2%)
|
1.00
1.00 – 1.00
+66.7% YoY
|
1.20
1.20 – 1.20
+20.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hui Liu | Vice President | — | male |
| Junfei Zhu | Vice President | — | male |
| Ming Tao | President & Non-Independent Director | — | male |
| Xiangdong Fan | Board Secretary, Vice President & Non-Independent Director | — | male |
| Xu Jie Li | Accounting Supervisor | — | — |
| Yunming Shangguan | Finance Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300637.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
